Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Malaria
Research conducted by F.B. Ntumngia and co-researchers has updated our knowledge about malaria
April 1st, 2009
"Plasniodium vivax Duffy binding protein (DBP) is vital for parasite development, thereby making this molecule a good vaccine candidate. Preclinical development of a P vivax vaccine often involves use of primate models prior to testing efficacy in humans, but primate isolates are poorly characterized," scientists in the United States report. "We analyzed the complete gene coding for the DBP in several P vivax isolates that are used for experimental primate infections and compared these sequences with the Salvador I DBP isolate, which is being used for vaccine development. Our results affirm that primate-adapted isolates are genetically similar to P vivax circulating in...
Source: Vaccine Weekly (2009-04-01)
|
